Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells $15,712.83 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 3,087 shares of the firm’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $5.09, for a total transaction of $15,712.83. Following the transaction, the chief operating officer now directly owns 109,241 shares of the company’s stock, valued at approximately $556,036.69. This represents a 2.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Robin Swartz also recently made the following trade(s):

• On Monday, December 23rd, Robin Swartz sold 6,500 shares of Voyager Therapeutics stock. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00.

Voyager Therapeutics Trading Up 2.8 %

NASDAQ VYGR traded up $0.14 on Wednesday, hitting $5.19. 398,045 shares of the company were exchanged, compared to its average volume of 397,579. The firm has a 50 day moving average of $6.04 and a two-hundred day moving average of $6.76. The company has a market cap of $283.51 million, a P/E ratio of 7.31 and a beta of 0.93. Voyager Therapeutics, Inc. has a 1-year low of $5.03 and a 1-year high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The company had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the prior year, the company posted ($0.59) EPS. Research analysts anticipate that Voyager Therapeutics, Inc. will post -0.89 EPS for the current fiscal year.

Institutional Trading of Voyager Therapeutics

Large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its stake in shares of Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after acquiring an additional 4,098 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Voyager Therapeutics during the 3rd quarter valued at $74,000. Victory Capital Management Inc. lifted its holdings in Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after purchasing an additional 1,630 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Voyager Therapeutics in the second quarter valued at about $128,000. Finally, Verition Fund Management LLC bought a new stake in shares of Voyager Therapeutics in the third quarter valued at about $216,000. 48.03% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on VYGR shares. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Leerink Partners initiated coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. Citigroup started coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective on the stock. Wedbush started coverage on shares of Voyager Therapeutics in a research report on Friday, November 29th. They issued an “outperform” rating and a $11.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics presently has an average rating of “Buy” and a consensus target price of $15.97.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.